Topical issues of prevention, diagnosis and treatment of vulvar and vaginal cancer
https://doi.org/10.17749/2313-7347.2018.12.4.062-070
Abstract
Vulvar cancer is a rare malignant tumor with the incidence rate of is 3–8 % of the total incidence of female genital malignant diseases. This disease is the 4th common cause of mortality (after cervical, endometrial and ovarian cancers) and accounts for 18.2 % of the total lethal outcomes. The anatomical structure of the external female organs with their extensive lymphatic and vascular networks contribute to the aggressive course, the trend to metastasize and rapid tumor growth. Progress in the timely diagnosis of vulvar and vaginal cancer is directly linked to increased competence and oncological vigilance among general practitioners and healthcare institutions. It is up to the primary care providers to identify women at risk or at the initial stages of cancer, and refer them to specialized medical facilities for further diagnostics and treatment. The high mortality from these diseases may be linked to the late detection and to the suboptimal therapy, which necessitates further research in this area.
About the Authors
A. G. Solopova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
MD, PhD, Professor, Department of Obstetrics and Gynecology, Faculty of Clinical and Preventive Medicine
62 St. Zemlyanoi Val, Moscow 109004, Russia
V. S. Moskvichyova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Clinical Resident, Department of Sports Medicine and Medical Rehabilitation, Faculty of General Medicine
62 St. Zemlyanoi Val, Moscow 109004, Russia
T. A. Blbulyan
Yerevan State Medical University named after Mkhitar Heratsi
Armenia
Armenia
Assistant, Department of Obstetrics and Gynecology
2 Koryun St., Yerevan 0025, Armenia
A. S. Shkoda
City Clinical Hospital № 67 named after L.A. Vorokhobov
Russian Federation
Russian Federation
MD, PhD, Professor, Chief Physician
2/44 Salyama Adilya St., Moscow 123423, Russia
A. D. Makatsariya
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
MD, PhD, Corresponding Member of RAS, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Clinical and Preventive Medicine
62 St. Zemlyanoi Val, Moscow 109004, Russia
References
1. Malignant neoplasms in Russia in 2014 (morbidity and mortality). [Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj]. Moskva: MNIOI im. P.A. Gercena – filial FGBU «NMIZC» MZ RF, 2016. 250 p (in Russ.).
2. Vorobyova L.I., Nespryadko S.V., Goncharuk I.V. et al. Vaginal cancer: current state of the problem. [Rak vlagalishcha: sovremennoe sostoyanie problemy]. Klinicheskaya onkoginekologiya. 2014;(1):46–50 (in Russ.).
3. Clinical oncogynecology: in 3 v. [Klinicheskaya onkoginekologiya: v 3 t. Pod red. F.Dzh. Disai, U.T. Krismana; per. s angl. pod red. E. G. Novikovoj]. Moskva: Rid Elsiver, 2011. 188 p (in Russ.).
4. Lai J., Elleray R., Nordin A. et al. Vulval cancer incidence, mortality and survival in England: age-related trends. BJOG. 2014;121(6):728–38.
5. Statistics of malignant neoplasms in Russia and the UIS countries in 2012. [Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2012 godu. Pod red. M.I. Davydova i E.M. Aksel']. Moskva: Izdatel'skaya gruppa RONC, 2014. 226 p (in Russ.).
6. Gynecology. National guideline. [Ginekologiya. Nacional'noe rukovodstvo. Pod red. G.M. Savel'evoj, G.T. Suhih, V.N. Serova, I.B. Manuhina, V.E. Radzinskogo]. Moskva: GEOTAR-Media, 2017. 1008 p (in Russ.).
7. Pushkarev V.A., Mazitov I.M., Khusnutdinov Sh.M., Golov E.K. Analysis of clinical and pathological peculiar properties of vulvar cancer. [Analiz kliniko-patologicheskih osobennostej raka vul'vy]. Medicinskij vestnik Bashkortostana. 2014;9(3):50–4 (in Russ.).
8. Pushkarev V.A., Mazitov I.M., Khusnutdinov Sh.M. Analysis of the clinical course of vulvar cancer. [Analiz klinicheskogo techeniya raka vul'vy]. Medicinskij vestnik Bashkortostana. 2012;7(2):87–90 (in Russ.).
9. Solopova A.G., Makatsaria A.D., Ivanov A.E., Malandin A.G. Precancer and cancer of the female external genital organs. [Predrak i rak zhenskih naruzhnyh polovyh organov]. Moskva: MIA, 2007. 80 p (in Russ.).
10. Suleymanova N.D. Risk factors for malignant tumors of the female genital organs. [Faktory riska zlokachestvennyh novoobrazovanij zhenskih polovyh organov]. Vestnik novyh medicinskih tekhnologij. 2014;21(1):115–21 (in Russ.).
11. Korzhevskaya E.V., Kravets O.A., Kuznetsov V.V., Khokhlova S.V. Clinical guidelines for the diagnosis and treatment of patients with vulvar squamous cell carcinoma. Moskva, 2014. 21 p (in Russ.). Available at: http://www.oncology.ru/association/clinicalguidelines/2014/06.pdf. [Accessed: 15.09.2018].
12. Korzhevskaya E.V., Kuznetsov V.V., Gritsay A.N. Malignant tumors of the vagina. In: Clinical oncogynecology: a guideline for doctors. [Zlokachestvennye opuholi vlagalishcha. V kn.:
13. Klinicheskaya onkoginekologiya: rukovodstvo dlya vrachej. Pod red. V.P. Kozachenko]. Moskva: Binom, 2016. 97–108 (in Russ.).
14. Alkatout I., Schubert M., Garbrecht N. et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;20(7):305–13.
15. Dellinger T.H, Hakim A.A, Lee S.J et al. Surgical management of vulvar cancer. J Natl Compr Canc Netw. 2017;15(1):121–8.
16. Tacastacas J.D., Bray J., Cohen Y.K. et al. Update on primary mucosal melanoma. J Am Acad Dermatol. 2014;71(2):366–75.
17. Siegel D.A., Wilson R., Wilkinson E.J. et al. Evaluation of the vulvar cancer histology code reported by central cancer registries: importance in epidemiology. Arch Pathol Lab Med. 2017;141(1):139–43.
18. Gritsay A.A., Korzhevskaya E.V., Kravets O.A., Kuznetsov V.V., Khokhlova S.V. Clinical guidelines for the diagnosis and treatment of patients with vaginal cancer. [Klinicheskie rekomendacii po diagnostike i lecheniyu bol'nyh rakom vlagalishcha]. Moskva, 2014. 11 p (in Russ.). Available at: http://www.oncology.ru/association/clinical-guidelines/2014/05.pdf. [Accessed: 15.09.2018].
19. Demidov L.V., Utiashev I.A., Kharkevich G.Yu. The role of vemurafenib in the treatment of disseminated melanoma of the skin. [Rol' vemurafeniba v lechenii disseminirovannoj melanomy kozhi]. Sovremennaya onkologiya. 2013;15(2):58–61 (in Russ.).
20. Mazurenko N.N. Genetic features and markers of melanoma of the skin. [Geneticheskie osobennosti i markery melanomy kozhi]. Uspekhi molekulyarnoj onkologii. 2014;1(2):26–35 (in Russ.).
21. Nerodo G.A., Zakharova N.P. The possibilities of radiodiagnosis of recurrent vulvar cancer. [Vozmozhnosti rentgenodiagnostiki recidivnogo raka vul'vy]. Mezhdunarodnyj zhurnal prikladnyh i fundamental'nyh issledovanij. 2015;8–2:251–3 (in Russ.).
22. Derdelis G., Pergialiotis V., Terzakis E. et al. The impact of inguinal lymph node micrometastases in patients with vulvar cancer. Arch Gynecol Obstet. 2017;295(2):435–8. DOI: 10.1007/s00404-016-4233-4.
23. Krikunov L.I., Mkrtchan L.S., Kaplan M.A. et al. The possibilities of photodynamic therapy of vulvar cancer. [Vozmozhnosti fotodinamicheskoj terapii raka vul'vy]. Radiaciya i risk. 2015;24(2):107–15 (in Russ.).
24. Dorney K.M., Growdon W.B., Clemmer J. et al. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgery for vulvar cancer. Gynecol Oncol. 2017;144(1):136–9.
25. Filonenko E.V., Chulkova OV, Serova L.G. Possibilities of photodynamic therapy in the treatment of degenerative diseases, intraepithelial neoplasias and vulvar cancer. [Vozmozhnosti fotodinamicheskoj terapii v lechenii distroficheskih zabolevanij, intraepitelial'nyh neoplazij i raka vul'vy]. Rossijskij bioterapevticheskij zhurnal. 2016;15(1):110–1 (in Russ.).
26. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. Br Med J. 2012;345:e6409.
27. Chokoeva A.A., Tchernev G., Castelli E. et al. Vulvar cancer: a review for dermatologists. Wien Med Wochenschr. 2015;165(7–8):164–77. DOI: 10.1007/s10354-015-0354-9.
28. Tsvetkov Ch., Gorchev G., Tomov S. et al. Prognostic models in modern management of vulvar cancer. Akush Ginekol (Sofiia). 2016;55(1):17–26.
29. Carter J., Stabile C., Seidel B. et al. Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors. J Cancer Surviv. 2017;11(2):274–83. DOI: 10.1007/s11764-016-0585-9.
30. Chhabra S., Bhavani M., Deshpande A. Trends of vulvar cancer. J Obstet Gynaecol. 2014;34(2):165–8.
31. Nedoro E.A., Nedoro G.A., Ivanova V.A. Analysis of recurrence timing and relapse-free survival in patients with vulvar cancer. [Analiz srokov poyavleniya recidivov i bezrecidivnoj vyzhivaemosti u bol'nyh rakom vul'vy]. Rossijskij medicinskij zhurnal. 2014;(2):18–21 (in Russ.).
Review
For citations:
Solopova A.G., Moskvichyova V.S., Blbulyan T.A., Shkoda A.S., Makatsariya A.D. Topical issues of prevention, diagnosis and treatment of vulvar and vaginal cancer. Obstetrics, Gynecology and Reproduction. 2018;12(4):62-70. (In Russ.) https://doi.org/10.17749/2313-7347.2018.12.4.062-070
Views:
979
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
